Grace Kho Dy
During the past decade, a number of novel agents developed for the treatment of advanced NSCLC had, by coincidence, shown survival benefit predominantly among patients with nonsquamous histology, namely pemetrexed (anti-folate), bevacizumab (VEGF pathway inhibition), erlotinib/gefitinib (EGFR receptor tyrosine kinase inhibitors) and crizotinib (ALK receptor tyrosine kinase inhibitor. This has sparked a heightened interest in discovering key molecular aberrations that may be relevant for the treatment of squamous cell carcinoma (SCC) of the lung, a histologic subtype that represents approximately 25% of lung cancer cases diagnosed globally. This article highlights the most promising recent discoveries and targeted agents in development that may be relevant for the treatment of SCC of the lung.
PDFShare this article
Cancer Science & Therapy received 5332 citations as per Google Scholar report
